The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases
Open accessAbstract
Sphingolipids represent a class of diverse bioactive lipid molecules that are increasingly appreciated as key modulators of diverse physiologic and pathophysiologic processes that include cell growth, cell death, autophagy, angiogenesis, and stress and inflammatory responses. Sphingomyelinases and ceramidases are key enzymes of sphingolipid metabolism that regulate the formation and degradation of ceramide, one of the most intensely studied classes of sphingolipids. Improved understanding of these enzymes that control not only the levels of ceramide but also the complex interconversion of sphingolipid metabolites has provided the foundation for the functional analysis of the roles of sphingolipids. Our current understanding of the roles of various sphingolipids in the regulation of different cellular processes has come from loss‐of‐function/gain‐of‐function studies utilizing genetic deletion/downregulation/overexpression of enzymes of sphingolipid metabolism (e.g. knockout animals, RNA interference) and from the use of pharmacologic inhibitors of these same enzymes. While genetic approaches to evaluate the functional roles of sphingolipid enzymes have been instrumental in advancing the field, the use of pharmacologic inhibitors has been equally important in identifying new roles for sphingolipids in important cellular processes.The latter also promises the development of novel therapeutic targets with implications for cancer therapy, inflammation, diabetes, and neurodegeneration. In this review, we focus on the status and use of pharmacologic compounds that inhibit sphingomyelinases and ceramidases, and we will review the history, current uses and future directions for various small molecule inhibitors, and will highlight studies in which inhibitors of sphingolipid metabolizing enzymes have been used to effectively treat models of human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, J.-T., Xu, J., Lee, J.-M., Ku, G., Han, X., Yang, D.-I., Chen, S., & Hsu, C. Y. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200307017 · Cited by 280
Identification of Ras farnesyltransferase inhibitors by microbial screening.
Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M., & Tamanoi, F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2281 · Cited by 257
Smith, E. L., & Schuchman, E. H. (2008) · The FASEB Journal · doi:10.1096/fj.08-108043 · Cited by 213
Cited by
Ceramide-orchestrated signalling in cancer cells
Morad, S. A. F., & Cabot, M. C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3398 · Cited by 1,014
Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane
Menck, K., Sönmezer, C., Worst, T. S., Schulz, M., Dihazi, G. H., Streit, F., Erdmann, G., Kling, S., Boutros, M., Binder, C., et al. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1378056 · Cited by 349
Cancer-associated lysosomal changes: friends or foes?
Kallunki, T., Olsen, O. D., & Jäättelä, M. (2013) · Oncogene · doi:10.1038/onc.2012.292 · Cited by 298
Targeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225
Switzer, C. H., Glynn, S. A., Ridnour, L. A., Cheng, R. Y.-S., Vitek, M. P., Ambs, S., & Wink, D. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.001 · Cited by 74
Metadata
- Authors
- Canals, D., Perry, D. M., Jenkins, R. W., & Hannun, Y. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-05-26
- Volume
- 163
- Issue
- 4
- Pages
- 694-712
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1583161747
- Cited by
- 162
- References
- 3
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01279.x
- The paper
- Canals, D., Perry, D. M., Jenkins, R. W., & Hannun, Y. A. (2011). Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01279.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.